

RA, biologisk behandling och förlorade arbetsdagar

Exempel på användning av svenska hälsodataregister

PRESENTATION SNS 2013 02 07

FINAL RAPPORT SEPTEMBER 2013

Fokus


Utveckling av förlorade arbetsdagar i relation till

- 1. diagnos av reumatoid artrit (RA)**
- 2. biologisk behandling vid etablerad & tidig RA**

Publikationer

1. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. *Ann Rheum Dis*. Jun 2006;65(6):707-712.
2. Neovius M, Simard J, Sundstrom A, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. *Ann Rheum Dis*. Mar 2011;70(3):516-519.
3. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of Rheumatoid Arthritis in Sweden - a nationwide population-based assessment of incidence, its determinants, and treatment penetration. *Arthritis Care Res (Hoboken)*. Dec 19 2012.
4. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. *Ann Rheum Dis*. Apr 2011;70(4):624-629.
5. Neovius M, Sundstrom A, Simard J, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. *Scand J Rheumatol*. Jan 2011;40(1):8-15.
6. Neovius M, Simard JF, Askling J. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? *Ann Rheum Dis*. Jun 2011;70(6):1010-1015.
7. Neovius M, Simard JF, Klareskog L, Askling J. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. *Ann Rheum Dis*. Aug 2011;70(8):1407-1414.
8. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet*. May 5 2012;379(9827):1712-1720.
9. Eriksson J, Neovius M, Bratt J, et al. Sick Leave and Disability Pension in Patients with Early RA Randomized to Infliximab+MTX or Triple Therapy: One-Year Results from the SWEFOT Trial. *ACR*. 2011;Abstract.

Data



Patientregistret
Slutenvård (1964-)
Öppenvård (2001-)

Swedish Rheumatology
Quality Register (1995-)

ARTIS (1999-)
Swedish Biologics Register

Läkemedels-
registret


SCB

Försäkringskassan

Cancer-
registret

Dödsorsaks-
registret


Reumatoid artrit



Biologisk behandling


Samtliga indikationer

- **Effektivt**
- **Ej ofarligt**
- **Dyrt**
≈135 000 kr per patientår




Förlorade arbetsdagar i relation till diagnos

max 30 dagar



Förlorade arbetsdagar i relation till biologisk behandling

Etablerad RA



RCT i berikat kvalitetsregister

MTX-refraktär tidig RA

PRELIMINÄRA DATA

Berikade kvalitetsregisterdata

Sammanfattning

- **Observera**
 - Användningsmönster
 - Sjukdomsbörda & kostnader

- **Infrastruktur för RCTs**
 - Identifiering & datainsamling
 - Relativ effekt & värde

Best of Both Worlds?

	Berikade kvalitetsregister	RCTs i berikade kvalitetsregister	Traditionell RCT
Duration	Lång <i>(till död/emigration)</i>	Lång	Kort
Antal utfall	Många	Många	Få
Kausalitet	Nej / Oklart	Ja	Ja
Generaliserbarhet	Mycket god	God	Begränsad